Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 629 results for "Victoza"

Novo Nordisk launches Victoza diabetes drug

WITH more than 387 million people 8.3 per cent of the global adult population believed to have diabetes worldwide, and additional 316 million people (6.9 per cent of the world adult population) having impaired glucose tolerance (IGT), which can ... The Guardian Nigeria, 3 days ago
Novo Nordisk Launches Vicotza Diabetes Drug, 3 days ago

US FDA clears diabetes drug for treatment of obesity

Liraglutide, was first approved in 2010 as a treatment for type 2 diabetes and is marketed for that indication as Victoza. Liraglutide will be marketed as Saxenda for the weight loss indication “and should not be used in combination with any other ...
 Asian Age1 month ago Injectable obesity drug approved  CNBC1 month ago Novo Nordisk Receives Positive Opinion In Europe On Obesity Treatment  Seeking Alpha2 days ago Novel drug from Novo Nordisk halts Type2 diabetes  Vanguard3 days ago
Pharma Letter

Novo Nordisk's Victoza granted label extension in the UK

A license extension has been granted in the UK for Victoza (liraglutide), an already blockbuster diabetes drug from Danish insulin giant Novo Nordisk (NOV: N). The once-daily injection has been approved for adults with type 2 diabetes and ...
 Pharma Letter4 days ago CHMP Approves Victoza  Nordic Life Science1 month ago Novo Nordisks (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP  Bidness Etc2 months ago CHMP reccommends approval of Victoza for use in adults with type 2 diabetes and moderate renal impairment  PharmaBiz2 months ago

Novo Nordisk's Victoza Recommended for Label Expansion

Novo Nordisk A/S ( NVO ) announced that Victoza (once-daily) has received a positive opinion from The Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of patients suffering from type II diabetes and moderate renal ...
 Yahoo! Finance2 months ago

BRIEF-Novo'S victoza receives positive opinion for use in adults with type 2 diabetes

COPENHAGEN Nov 21 (Reuters) - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission ...
 Reuters UK2 months ago

A Trial on the Effect of Combining Victoza and Invokana on Glycemic Control in Type 2 Diabetes

Clinical Trial Identifier: NCT02324842 This four-month trial is testing the effect of combining Victoza (liraglutide) and Invokana (canagliflozin) on several outcomes, including A1c and the liver's production of glucose in people with type 2 ...
 diaTribe1 day ago

EC Grants Extension to Victoza

Frankfurt, Germany BIO-Europe , November 3-5, Frankfurt, Germany European Statistical Forum , November 17, Brussels, Belgium SwedenBIO CEO Summit , December 3, Stockholm, Sweden Biotech Showcase 2015 , January 12-14, San Fransisco, CA, ...
 Nordic Life Science3 days ago

A Potential Game-Changer in Type 2 Diabetes: GLP-1 Agonist/ Basal Insulin Combinations?

By Emily Regier Twitter summary: The scoop on GLP-1 agonist/basal insulin combos how they work, why were so excited about them, and what's on the horizon Short summary: GLP-1 agonist/basal insulin combinations are some of the most exciting ...
 diaTribe1 day ago Basal Insulin With Incretin GLP-1 Receptor Agonists for T2DM  General Medicine eJournal1 month ago

European Medicines Agency Release: Novo Nordisk A/S (NVO)'s Saxenda Recommended For Approval In Weight Management In Adults 1/23/2015

Medicine to be used in addition to reduced-calorie diet and physical activity The European Medicines Agency has recommended granting a marketing authorisation for Saxenda (liraglutide) for weight management in overweight or obese adults. The ...
 ClinicSpace2 days ago News and press releases: Saxenda recommended for approval in weight management in adults  European Medicines Agency2 days ago
Pharma Letter

Swiss to Launch Diabetes Drug

Novo Nordisk announced that Switzerland is the first country to launch Xultophy ® (IDegLira) for people with type 2 diabetes. Xultophy ® is the first combination of a basal insulin [Tresiba ® (insulin degludec)] and a GLP-1 analogue [Victoza ® ...
 Nordic Life Science3 days ago Novo Nordisk launches Xultophy in Switzerland to treat people with type 2 diabetes  PharmaBiz5 days ago Switzerland First Country to Launch Xultophy® (IDegLira)  ADVFN Australia6 days ago NOVO NORDISK A/S : -Switzerland first country to launch Xultophy (IDegLira)  4 Traders5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less